Sign in

    Nat Charoensook

    Research Analyst at Leerink Partners

    Nat Charoensook is Vice President of Biotechnology Equity Research at Leerink Partners, specializing in diversified biopharmaceuticals with a focus on companies such as Zymeworks Inc., Xencor, Zai Lab, Abivax SA, Aclaris Therapeutics, 89bio, Sensorion SA, Arcturus Therapeutics, and Voyager Therapeutics. He holds both a Ph.D. and CFA designation, and his track record includes coverage of numerous innovative biotech firms with a reported coverage universe market cap reaching billions, though specific public rankings such as TipRanks are not available. Charoensook began his analyst career in biotechnology and has played a key role at Leerink Partners since at least 2024, with earlier experience indicated by his ongoing coverage documents and professional credentials as a CFA charterholder. He is additionally registered with FINRA and maintains an active securities analyst license, distinguishing him as a recognized expert in the field.

    Nat Charoensook's questions to Viking Therapeutics (VKTX) leadership

    Nat Charoensook's questions to Viking Therapeutics (VKTX) leadership • Q2 2025

    Question

    Nat Charoensook, on for Thomas Smith of Leerink Partners, asked what the amylin agonist program would need to demonstrate in its Phase I trial, particularly relative to VK2735, to justify continued development.

    Answer

    President & CEO Brian Lian stated that the goal for the Phase I amylin study is to see an impact on body weight and to understand the tolerability profile. He noted that the industry has matured beyond focusing solely on 28-day weight loss data, and the decision to proceed will be based on the overall trajectory, safety, and tolerability.

    Ask Fintool Equity Research AI

    Nat Charoensook's questions to IMMUNIC (IMUX) leadership

    Nat Charoensook's questions to IMMUNIC (IMUX) leadership • Q4 2023

    Question

    Inquired about the expectations for the ENSURE study's interim futility analysis, the criteria for continuing development in RMS, and details for the planned Phase 2 celiac disease trial, including gating factors, trial size, and potential endpoints.

    Answer

    The ENSURE interim analysis is strictly for futility and will not include biomarker data; it may result in a sample size adjustment. The Phase 2 celiac disease study is being designed with potential for other GI indications, but it is not yet funded and the company is seeking partnerships.

    Ask Fintool Equity Research AI